NanoDetection Technology and Oligomerix Enter Exclusive Global Licensing Agreement to Advance Next-Generation Neurodegenerative Disease Diagnostics
NanoDetection Technology, Incorporated (NDT) and Oligomerix, Inc. have announced a significant strategic partnership through the execution of an exclusive worldwide licensing agreement focused on advancing the diagnosis and characterization of neurodegenerative diseases. The agreement grants NanoDetection exclusive global rights to develop and commercialize diagnostic products based on a proprietary portfolio of nine Tau antibodies discovered by Oligomerix, while Oligomerix retains ownership and development rights for therapeutic applications involving the antibody panel.
The collaboration brings together Oligomerix’s expertise in Tau biology and NanoDetection’s innovative diagnostic technologies, creating a powerful platform aimed at improving the detection and monitoring of Alzheimer’s disease and related neurodegenerative disorders. The partnership is expected to accelerate the development of advanced diagnostic tools capable of providing deeper insights into disease progression and protein aggregation processes that are central to many neurodegenerative conditions.
A New Approach to Understanding Neurodegenerative Disease
At the center of the agreement is Oligomerix’s proprietary collection of nine highly specialized Tau antibodies. These antibodies have gained recognition within the scientific community for their ability to identify and distinguish unique forms of the Tau protein that are closely associated with disease pathology.
Tau proteins play a critical role in maintaining the structural stability of nerve cells. However, in several neurodegenerative diseases, Tau proteins undergo abnormal changes that cause them to misfold, aggregate, and accumulate within brain tissue. These pathological changes are believed to contribute directly to neuronal dysfunction and cognitive decline.
Traditional diagnostic methods generally focus on measuring total Tau levels or specific phosphorylated forms of Tau. While these approaches provide valuable information, they often fail to capture the complex structural and conformational changes that occur as disease progresses.
The antibody panel licensed by NanoDetection offers a more sophisticated approach by enabling researchers and clinicians to differentiate among multiple disease-associated Tau species. These include cleavage-specific forms and conformationally altered variants found within the core structure of pathological Tau filaments.
This capability provides an unprecedented opportunity to examine how Tau proteins transition from healthy forms to aggregated disease-associated states. Such insights could help improve diagnostic accuracy and provide a clearer understanding of disease progression across multiple neurodegenerative conditions.
Potential to Differentiate Multiple Tau-Related Disorders
One of the most promising aspects of the licensed technology is its ability to distinguish between different Tau-driven neurodegenerative diseases.
While Alzheimer’s disease remains the most widely recognized Tau-related disorder, several other conditions also involve abnormal Tau accumulation. These include Frontotemporal Dementia (FTD), Progressive Supranuclear Palsy (PSP), and Corticobasal Degeneration (CBD), each of which presents unique pathological signatures and clinical manifestations.
Current diagnostic approaches often face challenges in differentiating among these disorders, particularly during early disease stages when symptoms may overlap. The specialized Tau antibodies licensed by NanoDetection may help overcome these limitations by identifying distinct molecular signatures associated with specific disease processes.
By enabling quantitative characterization of disease-associated protein aggregation, the technology has the potential to support more accurate diagnoses, improve patient stratification in clinical studies, and facilitate the development of targeted therapeutic strategies.
Researchers believe that better characterization of pathological Tau species could significantly enhance the ability to monitor disease progression and assess treatment effectiveness in future clinical applications.
Integration into the TRACE-Tau Platform
NanoDetection has already incorporated the licensed antibody portfolio into its proprietary TRACE-Tau™ platform, a diagnostic framework specifically designed to measure and monitor protein-state transitions associated with neurodegenerative disease.
The TRACE-Tau platform aims to move beyond conventional biomarker testing by providing quantitative measurements of aggregated and structurally altered Tau species throughout the disease continuum.
Through the integration of the Oligomerix antibodies, NanoDetection has established a novel analytical system capable of tracking how Tau proteins evolve during disease development. This approach may provide valuable information about disease stage, severity, and progression that cannot be captured through traditional assays.
The company believes that measuring these protein-state transitions could offer clinicians a more accurate representation of active disease pathology, ultimately supporting earlier intervention and improved patient management.
Deployment on the Luminorix Diagnostic System
The advanced Tau assays are being developed for deployment on NanoDetection’s proprietary Luminorix™ instrument platform. The system utilizes the company’s Accuglo™ chemiluminescent assay architecture, which is designed to deliver highly sensitive and quantitative measurements of biological targets.
The combination of TRACE-Tau, Luminorix, and Accuglo technologies creates a comprehensive diagnostic ecosystem capable of detecting subtle molecular changes associated with neurodegenerative disease.
According to NanoDetection, the platform is designed to offer high analytical sensitivity while maintaining the precision required for clinical and research applications. The company anticipates that these capabilities will help facilitate broader adoption of advanced protein characterization methods in both academic and healthcare settings.
As development continues, the company plans to refine assay performance and expand validation efforts across multiple biological sample types.
Encouraging Results from Human Sample Studies
NanoDetection has already generated promising data through the analysis of samples obtained from individuals diagnosed with Alzheimer’s disease.
According to the company, studies conducted using multiple patient samples have demonstrated the ability of the antibody-based assays to detect and characterize aggregated Tau species across a range of human specimen types. These findings support the translational relevance of the technology and suggest potential applicability in real-world clinical environments.
The ability to identify aggregated Tau forms in patient-derived samples represents an important milestone in validating the platform’s scientific foundation. Researchers continue to explore how these biomarkers correlate with disease severity, progression, and clinical outcomes.
By focusing on aggregated Tau species believed to be directly involved in disease pathology, the platform may provide information that is more clinically meaningful than traditional biomarker measurements alone.
Advancing Clinical Verification Through Academic Collaboration
To further validate the diagnostic technology, NanoDetection is collaborating with the UMass Chan Medical School Morphology and SCOPE cores. Together, the organizations are conducting additional studies aimed at verifying the performance and clinical utility of the platform.
One key area of investigation involves the analysis of cerebrospinal fluid (CSF), a biological sample that plays a crucial role in neurodegenerative disease diagnostics. Early validation efforts have produced encouraging results, supporting continued development and optimization of the assays.
Researchers hope that successful clinical verification will strengthen confidence in the platform’s ability to accurately characterize pathological Tau species and support its eventual introduction into clinical practice.
The ongoing collaboration reflects the growing importance of academic-industry partnerships in accelerating the development of innovative diagnostic technologies.
Leadership Highlights Strategic Importance of the Partnership
Executives from both organizations emphasized the significance of the licensing agreement and its potential impact on the future of neurodegenerative disease diagnostics.
Douglas Durand, Chief Executive Officer of NanoDetection Technology, described the agreement as a major strategic achievement for the company.
According to Durand, the Oligomerix antibody portfolio provides NanoDetection with a powerful scientific and commercial foundation for developing next-generation diagnostic platforms focused on protein characterization and neurodegenerative disease detection.
James Moe, Chief Executive Officer of Oligomerix, expressed enthusiasm about the collaboration and the opportunity to expand the impact of the company’s Tau-focused technologies.
Moe noted that the antibody portfolio may serve as an important tool for characterizing aggregated and conformationally altered Tau species associated with neurodegenerative diseases and related conditions. He also emphasized that the partnership allows Oligomerix to broaden the reach of its scientific innovations while continuing to pursue therapeutic development opportunities.
As neurodegenerative diseases continue to affect millions of individuals worldwide, the need for more precise diagnostic tools remains urgent. Earlier detection, improved disease characterization, and better monitoring capabilities are widely recognized as critical components in advancing patient care and accelerating therapeutic development.
The exclusive licensing agreement between NanoDetection Technology and Oligomerix represents an important step toward achieving these goals. By combining specialized Tau antibodies with advanced diagnostic platforms, the partnership aims to provide researchers and clinicians with powerful new tools for understanding and monitoring neurodegenerative disease.
As development and validation efforts progress, the companies hope their collaborative work will contribute to a new generation of diagnostics capable of transforming how Alzheimer’s disease and related Tauopathies are detected, characterized, and ultimately managed.
About NanoDetection Technology, Incorporated
Located in Franklin, Ohio, NanoDetection Technology develops advanced diagnostic platforms for complex diseases, including neurodegeneration, oncology, and infectious disease. Its Luminorix™ instrument system is designed to translate high-precision assay technologies into rapid clinical applications.
About Oligomerix, Incorporated
Headquartered in the Bronx, New York, Oligomerix is a clinical-stage biotechnology company focused on discovering and developing novel small-molecule inhibitors of protein self-association for Alzheimer’s disease and rare neurodegenerative disorders, including Progressive Supranuclear Palsy and Frontotemporal Dementia. Oligomerix’s lead compound, OLX-07010, has completed Phase 1a and is preparing to enter clinical trials in Alzheimer’s disease patients.
